Currently under development using the personalized healthcare (PHC) approach by Roche, MetMAb is indicated as a treatment for non-small cell lung cancer (NSCLC) and lebrikizumab for bronchial asthma.
The tie up allows Chugai to develop and market these compounds in Japan.
As per the terms of the agreement, Roche is eligible to receive milestone payments from Chugai.